Hartmut Ehrlich

USPTO Granted Patents = 26 (Patent Applications = 13)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 10 (Patent Applications = 19)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 80(Granted Patents)

Location History:

Vienna, AT (2011 - 2021)
Paris, FR (2019 - 2023)

Company Filing History:

12 out of 2,480

Baxter International Inc.

Ology Bioservices Inc.

patents

6. 2 out of 1,177

Takeda Pharmaceutical Company Limited

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...

26 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11826372 - Combinations including ABX196 for the treatment of cancer (2023-11-28),

2. 11793855 - TFPI inhibitors and methods of use (2023-10-24),

3. 11278552 - Combinations including ABX196 for the treatment of cancer (2022-03-22),

4. 11266667 - ABX196 for use in the treatment of bladder cancer (2022-03-08),

5. 11001613 - TFPI inhibitors and methods of use (2021-05-11),

6. 10494418 - IgG stimulated remyelination of peripheral nerves (2019-12-03),

7. 10329583 - Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses (2019-06-25),

8. 10201586 - TFPI inhibitors and methods of use (2019-02-12),

9. 9884105 - Production of viral vaccine (2018-02-06),

10. 9834593 - IgG stimulated remyelination of peripheral nerves (2017-12-05),

11. 9777051 - TFPI inhibitors and methods of use (2017-10-03),

12. 9556230 - TFPI inhibitors and methods of use (2017-01-31),

13. 9512198 - FVIII peptides for immune tolerance induction and immunodiagnostics (2016-12-06),

14. 9463237 - Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza A viruses (2016-10-11),

15. 9046536 - Methods and compositions for treating bleeding disorders (2015-06-02),

Title: Innovator Hartmut Ehrlich: Pioneering Advances in Cancer Treatment

Introduction

Hartmut Ehrlich, a distinguished inventor based in Vienna, Austria, has made significant contributions to the field of pharmaceuticals and medical innovations. With a remarkable portfolio of 26 patents, Ehrlich's work focuses predominantly on the development of treatments for cancer and blood coagulation disorders.

Latest Patents

Among his latest patents are innovative therapies that aim to combat cancer. One notable patent involves combinations including ABX196, an antitumor pharmaceutical that integrates a compound ABX196 with chemotherapeutic and/or immunotherapeutic agents for the enhancement of cancer treatment. Another important patent is centered around Tissue Factor Pathway Inhibitor (TFPI) inhibitors and their methods of use. This invention presents peptides that bind TFPI and offers a range of applications, including the enhancement of thrombin formation, treatment of blood coagulation disorders, and identification of TFPI-binding compounds.

Career Highlights

Hartmut Ehrlich's career features prominent roles at Baxter International Inc. and Baxter Healthcare. His tenure at these companies has allowed him to leverage his expertise in pharmaceuticals to develop groundbreaking therapeutic solutions.

Collaborations

Throughout his career, Ehrlich has collaborated with notable professionals in the industry, including Michael Dockal and Friedrich Scheiflinger. These partnerships have been instrumental in advancing his research and innovation in medical treatments.

Conclusion

In conclusion, Hartmut Ehrlich stands out as a pivotal figure in the sphere of medical innovation, particularly in the realm of cancer treatment. His extensive patent portfolio reflects a commitment to advancing healthcare through innovative solutions, positioning him as a leading inventor in his field.

This text is generated by artificial intelligence and may not be accurate.